2012 News

• 12.17.2012
  Press Release IR News

  Changes in Significant Shareholders

• 11.27.2012
  Press Release IR News

  Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)

• 11.27.2012
  Press Release IR News

  Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration

• 11.01.2012
  Press Release IR News

  Santen Announces Financial Result for the Second Quarter ended September 30, 2012

• 11.01.2012
  Press Release IR News

  Notice of Cancellation of Treasury Shares

• 10.03.2012
  Press Release IR News

  Santen to Renew the Sante 40 OTC Eye Drop Series

• 09.28.2012
  Press Release IR News

  Intravitreal VEGF Inhibitor "EYLEA Solution for Intravitreal Injection" and "EYLEA Intravitreal Injection KIT" Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan

• 09.25.2012
  Press Release IR News

  Notice on the Establishment of a New Sales and Marketing Company in China

• 09.25.2012
  Press Release IR News

  Eisai and Santen Enter into Option Agreement for New Ophthalmic Drugs

• 08.30.2012
  Press Release IR News

  Notification Regarding Result and Completion of Acquisition of Treasury Stock and Tender Offer of Treasury Stock

• 08.01.2012
  Press Release IR News

  Santen Announces Financial Result for the First Quarter ended June 30, 2012

• 08.01.2012
  Press Release IR News

  Notice of Acquisition and Tender Offer of Treasury Stock

• 07.04.2012
  Press Release IR News

  Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)

• 06.25.2012
  Press Release IR News

  FDA Approves enVista, a Single-Piece Intraocular Lens, Made from the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS

• 06.20.2012
  Press Release IR News

  Notice on the Allotment of Stock Options (Stock Acquisition Rights)

• 05.08.2012
  Press Release IR News

  Santen Announces Financial Results for the Year ended March 31, 2012

• 05.08.2012
  Press Release IR News

  Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Directors

• 05.08.2012
  Press Release IR News

  Santen to Issue Rights to Subscribe for New Shares as Stock Options in favor of Corporate Officers

• 05.08.2012
  Press Release IR News

  Notice of the Nominations for the members of the Board of Directors

• 05.08.2012
  Press Release IR News

  Announcement of the conclusion of the agreement on co-promotion of VEGF Trap-Eye (aflibercept intravitreal injection)

• 03.09.2012
  Press Release IR News

  Notice of the appointment of Corporate Officers

• 03.01.2012
  Press Release IR News

  Santen to Launch Sante Medical Guard OTC Eye Drop

• 02.14.2012
  Press Release IR News

  FDA Approves ZIOPTAN (tafluprost ophthalmic solution),Merck's Once-Daily, Preservative-Free Ophthalmic Medication

• 02.07.2012
  Press Release IR News

  Santen Announces Financial Result for the Third Quarter ended December 31, 2011

• 02.07.2012
  Press Release IR News

  Notice on the Establishment of Holding Company in Europe

• 01.24.2012
  Press Release IR News

  Santen to Launch Nutritional Supplement Sante Lutax 20 + DHA

News Archive